



OPEN ACCESS

EDITED AND REVIEWED BY

Annalisa Capuano,
University of Campania Luigi Vanvitelli,
Italy

*CORRESPONDENCE

Gianluca Dini,
✉ gianlucadini90@gmail.com

SPECIALTY SECTION

This article was submitted to Obstetric
and Pediatric Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 05 December 2022

ACCEPTED 21 December 2022

PUBLISHED 05 January 2023

CITATION

Dini G, Tulli E, Dell'Isola GB, Mencaroni E,
Di Cara G, Striano P and Verrotti A (2023),
Corrigendum: Improving therapy of
pharmacoresistant epilepsies: The role
of fenfluramine.
Front. Pharmacol. 13:1116575.
doi: 10.3389/fphar.2022.1116575

COPYRIGHT

© 2023 Dini, Tulli, Dell'Isola, Mencaroni, Di
Cara, Striano and Verrotti. This is an open-
access article distributed under the terms
of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine

Gianluca Dini^{1*}, Eleonora Tulli¹, Giovanni Battista Dell'Isola¹,
Elisabetta Mencaroni¹, Giuseppe Di Cara¹, Pasquale Striano^{2,3} and
Alberto Verrotti¹

¹Department of Pediatrics, University of Perugia, Perugia, Italy, ²Pediatric Neurology and Muscular Diseases
Unit, IRCCS "G. Gaslini" Institute, Genoa, Italy, ³Department of Neurosciences, Rehabilitation,
Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy

KEYWORDS

fenfluramine, pharmacoresistant epilepsy, Dravet syndrome, Lennox-Gastaut syndrome,
anti-seizure medication (ASM)

A Corrigendum on Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine

by Dini G, Tulli E, Dell'Isola GB, Mencaroni E, Di Cara G, Striano P and Verrotti A (2022). *Front.
Pharmacol.* 13:832929. doi: 10.3389/fphar.2022.832929

In the published article, there was an error. The conclusions of the article should be more cautionary and provide a more objective stance on the benefits and risks of this drug and its use. As such, a correction has been made to the **Conclusion**, final sentence. The original sentence reads as follows: "FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, pointing out that significant benefits outweigh potential cardiac risks."

The corrected sentence appears below: "FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, suggesting that benefits might outweigh potential cardiac risks, although this will need to be established in targeted investigations."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.